Publications by authors named "Faivre Laura"

Claim this Profile
T
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.
Shanna Rajpar, Tony Ibrahim, Alexandra Carmel, Zahira Merabet, Philippe Vielh, Laura Faivre

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Valentina Orlando, Damien Drubay, Pernelle Lavaud, Laura Faivre, François Lesaunier

Clin Genitourin Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Vianney Poinsignon, Laura Faivre, Laurent Nguyen, Benedicte Neven, Sophie Broutin

Pediatr Blood Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
Yungan Tao, Laura Faivre, Anne Laprie, Pierre Boisselier, Christophe Ferron

Radiother Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Jean-Marie Michot, Lina Benajiba, Laura Faivre, Capucine Baldini, Lelia Haddag

Invest New Drugs· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Charlotte Leduc, Julien Adam, Emilie Louvet, Tony Sourisseau, Nicolas Dorvault, Laura Faivre

ESMO Open· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study.
Bluthgen Maria Virginia, Faivre Laura, Rosellini Silvia, Ferrara Roberto, Facchinetti Francesco

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.
Laura Mezquita, Melinda Charrier, Laura Faivre, Louise Dupraz, Béranger Lueza

Lung Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Francesco Facchinetti, Maria Virginia Bluthgen, Gabrielle Tergemina-Clain, Laura Faivre, Jean-Pierre Pignon

Lung Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.
Lina Benajiba, Jean-Marie Michot, Capucine Baldini, Laura Faivre, Andrea Varga

Anticancer Drugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study of Intrapatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography.
Nathalie Lassau, Bénédicte Coiffier, Laura Faivre, Baya Benatsou, Sophie Bidault

Invest Radiol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Pierre Blanchard, Laura Faivre, François Lesaunier, Naji Salem, Nathalie Mesgouez-Nebout

Int J Radiat Oncol Biol Phys· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Karim Fizazi, Laura Faivre, François Lesaunier, Remy Delva, Gwenaëlle Gravis

Lancet Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis